Quick Answer
AbCellera Biologics Inc. reported R&D Expense of $186.83 million for fiscal year 2025.
AbCellera Biologics Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $186.83M | +11.7% |
| 2024 | $167.26M | -4.8% |
| 2023 | $175.66M | +62.8% |
| 2022 | $107.88M | +73.8% |
| 2021 | $62.06M | +111.1% |
| 2020 | $29.39M | +190.6% |
| 2019 | $10.11M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $55.03M | +34.3% | +40.3% |
| June 30, 2025 | $39.21M | -4.2% | -7.7% |
| March 31, 2025 | $42.50M | +8.2% | +3.7% |
| September 30, 2024 | $40.97M | +8.0% | +0.1% |
| June 30, 2024 | $40.93M | +12.2% | +4.2% |
| March 31, 2024 | $39.29M | -25.4% | +3.6% |
| September 30, 2023 | $37.92M | +42.6% | +4.0% |
| June 30, 2023 | $36.47M | +36.7% | -30.7% |
- AbCellera Biologics Inc. showed an increase of +11.7% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, AbCellera Biologics Inc.’s r&d expense has grown by 1747.4% (from $10.11 million to $186.83 million).
- The most recent figure is from AbCellera Biologics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: